Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.
Clene Announces Publication Of Phase 2 CNM-Au8 Clinical Data For The Treatment Of ALS In LANCET’s eClinicalMedicine
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up
SALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) -- Clene
